Stefan S. Bielack

Learn More
PURPOSE To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the(More)
PURPOSE To evaluate the impact of patient, tumor, and treatment-related factors on outcome in unselected patients with recurrent osteosarcoma. PATIENTS AND METHODS Five hundred seventy-six consecutive patients who had achieved a first complete surgical remission (CR) during combined-modality therapy on neoadjuvant Cooperative Osteosarcoma Study Group(More)
BACKGROUND High-dose methotrexate (HDMTX)-induced renal dysfunction can be life threatening, because it delays methotrexate (MTX) excretion, thereby exacerbating the other toxicities of MTX. HDMTX-induced nephrotoxicity has been managed with high-dose leucovorin, dialysis-based methods of MTX removal, thymidine, and with the recombinant enzyme,(More)
Writing committee: N. Athanasou, S. Bielack, E. De Alava, A. P. Dei Tos, S. Ferrari, H. Gelderblom, R. Grimer, K. Sundby Hall, B. Hassan, P. C. W. Hogendoorn, H. Jurgens, M. Paulussen, L. Rozeman, A.H.M. Taminiau, J. Whelan D. Vanel University of Oxford, Oxford, UK; Olgahospital, Stuttgart, Germany; Campus MigueldeUnamuno, Salamanca, Spain; Ospedale Civile,(More)
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65% to 70% after(More)
Ewing’s sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up M. Paulussen, S. Bielack, H. Jürgens & L. Jost On behalf of the ESMO Guidelines Working Group* Department of Pediatric Oncology/Hematology, University Children’s Hospital Basel (UKBB), Basel, Switzerland; Department of Pediatric Oncology and Hemaology,(More)
BACKGROUND In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre- and postoperatively to an already aggressive three-drug regimen. In a subgroup of patients, loco-regional treatment intensification was attempted by using the intraarterial route to give cisplatin. PATIENTS AND METHODS Patients < or = 40 years at diagnosis of a(More)
PURPOSE To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. PATIENTS AND METHODS Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases.(More)
PURPOSE The prognosis of osteosarcoma occurring as a second malignant disease (OS-SMD) is thought to be poor. We attempted to evaluate whether this holds true when OS-SMD is treated with combined modality therapy as developed for primary osteosarcoma and if factors that influence survival might be identified. PATIENTS AND METHODS All patients with OS-SMD(More)
BACKGROUND Mesenchymal chondrosarcoma (MCS) is a rare tumor with a strong tendency toward late recurrences leading to reported 10-year survival rates below 50%. The recommended treatment is resection with wide margins; the effectiveness of chemo- and radiotherapy remain poorly defined. As reports about MCS in young patients are scarce, treatment and(More)